Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 947-952

  Tricot, Guido ^a,c   Alberts, David S ^b   Johnson, Cynthia ^b   Roe, Denise J ^b   Dorr, Robert T ^b   Bracy, Dwayne ^a   Vesole, David H ^a   Jagannath, Sundar ^a   Meyers, Ross ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEPHROTOXICITY; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 8944232863     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Barlogie, B., Alexanian, R., Smallwood, L., Cheson, B., Dixon, D., Dicke, K., and Cabanillas, F. Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood, 72: 2015-2019, 1988.
2. Selby, P., McElwain, T., Nandi, A. C., Perren, T. J., Powles, R. L., Tillyer, C. R., Osborne, R. J., Slevin, M. L., and Malpas, J.S. Multiple myeloma treated with high-dose intravenous melphalan. Br. J. Haematol., 66: 55-62, 1987.
3. Jagannath, S , Vesole, D., Glenn, L , Crowley, J., and Barlogie, B. Low-risk intensive therapy for multiple myeloma with combined autologous bone roarrow and blood stem cell support. Blood, 80: 1666-1672, 1992.
4. Attal, M., Huguet, F., Schlaifer, D., Payen, C , Laroche, M., Fournie, B., Mazieres, B., Pris, J., and Laurent, G. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 79: 1130-1136, 1992.
5. Fermand, J., Chevret, S., Ravaud, P., Divine, M., Leblond, V., Dreyfus, F., Mariette, X., and Brouet, J. C. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood, 82: 2005-2009, 1993.
6. Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J , Viner, C., and Malpas, J. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol., 12: 759-763, 1994.
7. Dimopolous, M., Alexanian, R., Przepiorka, D., Hester, J., Andersson, B., Giralt, S , Mehra, R., van Besien, K., Delasalle, K. B., and Reading, C. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma Blood, 82: 2324-2328, 1993.
8. Harousseau, J., Milpied, N., Laporte, J., Collombat, P., Facon, T., Tigaud, J. D., Casassus, P., Guilhot, F., Ifrah, N., and Gandhour, C. Double-intensive therapy in high-risk multiple myeloma. Blood, 79: 2827-2833, 1992.
9. Barlogie, B., Jagannath, S., Vesole, D., Tricot, G., Naucke, S., Copeland, N., and Crowley, J. Total therapy for newly diagnosed multiple myeloma, Blood, 82 (Suppl. 1): 198a, 1993.
10. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, G., Rossi, J. F., Casassus, P., Thyss, A., Maisonneuve, H., Facon, T., Ifrah, N., Paven, C., and Bataille, R. High dose therapy in multiple myeloma: a prospective randomized study of the "Intergroupe Francais du Myelome" (IFM). Blood. 84 (Suppl. 1): 386a, 1994.
11. Sarosy, G., Leyland-Jones, B., Soochan, P., and Cheson, B. D. The systemic administration of intravenous melphalan. J. Clin Oncol., 6: 1768-1782, 1988.
12. Alberts, D. S., Chang, S. Y., Chen, H-S. G., Moon, T. E., Evans, T. L., Furner, R. L., Himmelstein, K., and Gross, J. F. Kinetics of intravenous melphalan. Clin. Pharmacol. Ther., 26: 73-80, 1979.
13. Bosanquet, A. G., and Gilby, E. D. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur. J. Cancer Clin. Oncol., 18: 355-362, 1982.
14. Speed, D. E., Galton, D. A. G., and Swan, A. Melphalan in the treatment of myelomatosis. Br. Med. J., 1: 1964-1969, 1964.
15. Zucchetti, M., D'Incalci, M., Willems, Y., Cavalli, F., and Serra, C. Lack of effect of cisplatin on IV L-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemother. Pharmacol., 22: 87-89, 1988.
16. Osterborg, A., Ehrsson, H., Eksborg, S., Watlin, I., and Mellistedt, H. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur. J. Cancer Clin. Oncol., 25: 899-903, 1989.
17. Barlogie, B., Alexanian, R., and Jagannath, S. Plasma cell dyscrasias. J. Am. Med. Assoc., 268: 2946-2951, 1992.
18. Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C., Malpas, J., Slevin, M., Findlay, M., Raymond, J, and Gore, M. E. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol., 12: 759-763, 1994.
19. Mansi, J., da Costa, F., Viner, C., Judson, I., Gore, M., and Cunningham, D. High-dose busulfan in patients with myeloma. J. Clin. Oncol., 10. 1569-1573, 1992.
20. Chang, S. Y., Alberts, D. S., Farquhar, D., Melnick, L. R., Walson, T. D., and Salmon, S. E. Hydrolysis and protein binding of melphalan. J. Pharm. Sci., 67: 682-684, 1978.
21. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
22. Jelliffe, R. W. Creatinine clearance bedside estimate. Ann. Intern. Med., 79: 604-605, 1973.
23. Gera, S., Musch, E., Osterheld, K., and Loos, J. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother. Pharmacol., 23: 76-80, 1989.
24. Kergueris, M. F., Milpied, N., Moreau, P., Harousseau, J. L., and Larousse, C. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res., 14: 2379-2382, 1994.
25. Jagannath, S., Vesole, D., Tricot, G., and Barlogie, B. 118 outpatient (OPT) autotransplants in multiple myeloma (MM). Blood, 84 (Suppl. 1): 212a, 1994.
26. Cuckle, H., Galton, D. A. G., Peto, R., Paul, E., and Gilham, M. Report on the second myelomatosis trial after five years of follow-up. Br. J. Cancer, 42: 813-822, 1980.
27. Dulik, D., and Fenselau, C. Conversion of melphalan to 4-(glutathionyl) phenylalanine. Drug Metab. Dispos., 15: 195-199, 1957.
28. Hercebergs, A., Brok-Simoni, F., Holtzman, F., Bar-Am, J., Leith, J. T., and Brenner, H. J. Erythrocyte glutathione and tumour response to chemotherapy. Lancet 339: 1074-1076, 1992.
29. Engin, A. Differences in blood glutathione levels of patients with advanced or localized carcinoma. Tumori, 81: 132-134, 1995.
30. Reece, P., Hill, H., Green, M., Morris, R., Dale, B., Kotasek, D., and Sage. R. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother. Pharmacol., 22: 348-352, 1988.
31. Ploin, D. Y., Tranchand, B , Guastalla, J-P., Rebattu, P., Chauvin, F., Clavel, M., and Ardiet, C. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur. J. Cancer, 28A: 1311-1315, 1992.